Skip to main content
SpringerLink
Log in

Cerebrospinal Fluid Biomarkers of Preclinical Alzheimer’s Disease

  • Protocol
  • First Online:
Biomarkers for Preclinical Alzheimer’s Disease

Part of the book series: Neuromethods ((NM,volume 137))

Abstract

The recent paradigm shift toward a more biologically oriented definition of Alzheimer’s disease (AD) in clinical settings increases the importance of biomarkers of AD. The established cerebrospinal fluid (CSF) biomarkers of AD, reflecting both amyloidopathy and tauopathy, are being increasingly incorporated into both diagnostic guidelines, enabling the diagnosis of AD independently of clinical symptoms, and inclusionary criteria for clinical trials. The present chapter provides an overview of the clinical utility of the three established CSF AD biomarkers and covers both clinical and methodological issues. A brief summary is given on relevant laboratory techniques to determine levels of AD CSF biomarkers; methodological and clinical challenges in the field are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. De-Paula VJ, Radanovic M, Diniz BS et al (2012) Alzheimer's disease. Subcell Biochem 65:329–352. https://doi.org/10.1007/978-94-007-5416-4_14

    Article  CAS  PubMed  Google Scholar 

  2. Kocahan S, Dogan Z (2017) Mechanisms of Alzheimer's disease pathogenesis and prevention: the brain, neural pathology, N-methyl-D-aspartate receptors, tau protein and other risk factors. Clin Psychopharmacol Neurosci 15(1):1–8. https://doi.org/10.9758/cpn.2017.15.1.1

    Article  PubMed  PubMed Central  Google Scholar 

  3. Alexopoulos P, Kurz A (2015) The new conceptualization of Alzheimer's disease under the microscope of influential definitions of disease. Psychopathology 48(6):359–367. https://doi.org/10.1159/000441327

    Article  PubMed  Google Scholar 

  4. McKhann GM (2011) Changing concepts of Alzheimer disease. JAMA 305(23):2458–2459. https://doi.org/10.1001/jama.2011.810

    Article  CAS  PubMed  Google Scholar 

  5. McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34(7):939–944

    Article  CAS  PubMed  Google Scholar 

  6. McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3):263–269. https://doi.org/10.1016/j.jalz.2011.03.005

    Article  PubMed  PubMed Central  Google Scholar 

  7. Forlenza OV, Radanovic M, Talib LL et al (2015) Cerebrospinal fluid biomarkers in Alzheimer's disease: diagnostic accuracy and prediction of dementia. Alzheimers Dement (Amst) 1(4):455–463. https://doi.org/10.1016/j.dadm.2015.09.003

    Google Scholar 

  8. Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3):270–279. https://doi.org/10.1016/j.jalz.2011.03.008

    Article  PubMed  PubMed Central  Google Scholar 

  9. Perneczky R, Pohl C, Sorg C et al (2006) Complex activities of daily living in mild cognitive impairment: conceptual and diagnostic issues. Age Ageing 35(3):240–245. https://doi.org/10.1093/ageing/afj054

    Article  PubMed  Google Scholar 

  10. Dubois B, Hampel H, Feldman HH et al (2016) Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 12(3):292–323. https://doi.org/10.1016/j.jalz.2016.02.002

    Article  PubMed  Google Scholar 

  11. Jack CR, Knopman DS, Jagust WJ et al (2013) Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. The Lancet Neurology 12(2):207–216. https://doi.org/10.1016/S1474-4422(12)70291-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Martins-de-Souza D (2010) Is the word 'biomarker' being properly used by proteomics research in neuroscience? Eur Arch Psychiatry Clin Neurosci 260(7):561–562. https://doi.org/10.1007/s00406-010-0105-2

    Article  PubMed  PubMed Central  Google Scholar 

  13. Engelborghs S (2013) Clinical indications for analysis of Alzheimer's disease CSF biomarkers. Rev Neurol (Paris) 169(10):709–714. https://doi.org/10.1016/j.neurol.2013.07.024

    Article  CAS  Google Scholar 

  14. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group (1998) Consensus report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”. Neurobiol Aging 19(2):109–116

    Article  Google Scholar 

  15. Olsson B, Lautner R, Andreasson U et al (2016) CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. The Lancet Neurology 15(7):673–684. https://doi.org/10.1016/S1474-4422(16)00070-3

    Article  CAS  PubMed  Google Scholar 

  16. Blennow K, Zetterberg H, Fagan AM (2012) Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med 2(9):a006221. https://doi.org/10.1101/cshperspect.a006221

    Article  PubMed  PubMed Central  Google Scholar 

  17. Molinuevo JL, Blennow K, Dubois B et al (2014) The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's biomarkers standardization initiative. Alzheimers Dement 10(6):808–817. https://doi.org/10.1016/j.jalz.2014.03.003

    Article  PubMed  Google Scholar 

  18. Lewczuk P, Esselmann H, Otto M et al (2004) Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging 25(3):273–281. https://doi.org/10.1016/S0197-4580(03)00086-1

    Article  CAS  PubMed  Google Scholar 

  19. Bibl M, Mollenhauer B, Esselmann H et al (2006) CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies. J Neural Transm (Vienna) 113(11):1771–1778. https://doi.org/10.1007/s00702-006-0537-z

    Article  CAS  Google Scholar 

  20. Bateman RJ, Xiong C, Benzinger TLS et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367(9):795–804. https://doi.org/10.1056/NEJMoa1202753

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Stomrud E, Minthon L, Zetterberg H et al (2015) Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: a prospective 9-year study. Alzheimers Dement (Amst) 1(4):403–411. https://doi.org/10.1016/j.dadm.2015.09.002

    Google Scholar 

  22. Sutphen CL, Jasielec MS, Shah AR et al (2015) Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol 72(9):1029–1042. https://doi.org/10.1001/jamaneurol.2015.1285

    Article  PubMed  PubMed Central  Google Scholar 

  23. Braak H, Zetterberg H, Del Tredici K et al (2013) Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-beta changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol 126(5):631–641. https://doi.org/10.1007/s00401-013-1139-0

    Article  CAS  PubMed  Google Scholar 

  24. Teunissen CE, Willemse E (2013) Cerebrospinal fluid biomarkers for Alzheimer's disease: emergence of the solution to an important unmet need. EJIFCC 24(3):97–104

    CAS  PubMed  Google Scholar 

  25. Hansson O, Zetterberg H, Buchhave P et al (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5(3):228–234. https://doi.org/10.1016/S1474-4422(06)70355-6

    Article  CAS  PubMed  Google Scholar 

  26. Parnetti L, Chiasserini D, Eusebi P et al (2012) Performance of abeta1-40, abeta1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. J Alzheimers Dis 29(1):229–238. https://doi.org/10.3233/JAD-2011-111349

    CAS  PubMed  Google Scholar 

  27. Mattsson N, Zetterberg H, Hansson O et al (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302(4):385–393. https://doi.org/10.1001/jama.2009.1064

    Article  CAS  PubMed  Google Scholar 

  28. Riedl L, Mackenzie IR, Forstl H et al (2014) Frontotemporal lobar degeneration: current perspectives. Neuropsychiatr Dis Treat 10:297–310. https://doi.org/10.2147/NDT.S38706

    PubMed  PubMed Central  Google Scholar 

  29. Alexopoulos P, Eisele T (2014) Efficiency of the ratio of cerebrospinal fluid Aβ42/Aβ40 concentrations in detecting Alzheimer's disease: a step forwards. Alzheimers Dement 10(4):P799

    Article  Google Scholar 

  30. Dubois B, Feldman HH, Jacova C et al (2014) Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 13(6):614–629. https://doi.org/10.1016/S1474-4422(14)70090-0

    Article  PubMed  Google Scholar 

  31. Kang J-H, Korecka M, Toledo JB et al (2013) Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β1–42 and τ proteins as Alzheimer disease biomarkers. Clin Chem 59(6):903–916. https://doi.org/10.1373/clinchem.2013.202937

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Vignali DA (2000) Multiplexed particle-based flow cytometric assays. J Immunol Methods 243(1–2):243–255

    Article  CAS  PubMed  Google Scholar 

  33. Dunbar SA and Li D (2010) Introduction to Luminex® xMAP® Technology and Applications for Biological Analysis in China. Asia Pac Biotech 14(10):26–30

    Google Scholar 

  34. Meso Scale Discovery®. MSD sector and quickplex plates, 18075-v2-2014 Jul. www.mesoscale.com

  35. Mattsson N, Andreasson U, Persson S et al (2013) CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 9(3):251–261. https://doi.org/10.1016/j.jalz.2013.01.010

    Article  PubMed  PubMed Central  Google Scholar 

  36. Mattsson N, Andreasson U, Persson S et al (2011) The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7(4):386–395.e6. https://doi.org/10.1016/j.jalz.2011.05.2243

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Lam B, Masellis M, Freedman M et al (2013) Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome. Alzheimers Res Ther 5(1):1. https://doi.org/10.1186/alzrt155

    Article  PubMed  PubMed Central  Google Scholar 

  38. Alexopoulos P, Roesler J, Thierjung N et al (2015) Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 266(7):587–597. https://doi.org/10.1007/s00406-015-0628-7

    Article  PubMed  Google Scholar 

  39. Perneczky R, Alexopoulos P, Kurz A (2014) Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers. Trends Mol Med 20(1):8–15

    Article  CAS  PubMed  Google Scholar 

  40. Maier W (2016) Searching biomarkers for mental disorders-lessons from Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 266(7):583–585. https://doi.org/10.1007/s00406-016-0732-3

    Article  CAS  PubMed  Google Scholar 

  41. Perneczky R, Guo L-H (2016) Plasma proteomics biomarkers in Alzheimer’s disease: latest advances and challenges. Methods Mol Biol 1303:521–529. https://doi.org/10.1007/978-1-4939-2627-5_32

    Article  PubMed  Google Scholar 

  42. Duits FH, Martinez-Lage P, Paquet C et al (2016) Performance and complications of lumbar puncture in memory clinics: results of the multicenter lumbar puncture feasibility study. Alzheimers Dement 12(2):154–163. https://doi.org/10.1016/j.jalz.2015.08.003

    Article  PubMed  Google Scholar 

  43. Blennow K, Wallin A, Hager O (1993) Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol Scand 88(3):221–223

    Article  CAS  PubMed  Google Scholar 

  44. Zetterberg H, Tullhog K, Hansson O et al (2010) Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients. Eur Neurol 63(6):326–330. https://doi.org/10.1159/000311703

    Article  PubMed  Google Scholar 

  45. Bittner T, Zetterberg H, Teunissen CE et al (2016) Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of beta-amyloid (1-42) in human cerebrospinal fluid. Alzheimers Dement 12(5):517–526. https://doi.org/10.1016/j.jalz.2015.09.009

    Article  PubMed  Google Scholar 

  46. Mattsson N, Zegers I, Andreasson U et al (2012) Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid beta42. Biomark Med 6(4):409–417. https://doi.org/10.2217/bmm.12.39

    Article  CAS  PubMed  Google Scholar 

  47. Vanderstichele H, Bibl M, Engelborghs S et al (2012) Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's biomarkers standardization initiative. Alzheimers Dement 8(1):65–73. https://doi.org/10.1016/j.jalz.2011.07.004

    Article  CAS  PubMed  Google Scholar 

  48. Cicognola C, Chiasserini D, Eusebi P et al (2016) No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF. Mol Neurodegener 11(1):65. https://doi.org/10.1186/s13024-016-0130-3

    Article  PubMed  PubMed Central  Google Scholar 

  49. Zimmermann R, Lelental N, Ganslandt O et al (2011) Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics. J Alzheimers Dis 25(4):739–745. https://doi.org/10.3233/JAD-2011-110212

    CAS  PubMed  Google Scholar 

  50. Bjerke M, Portelius E, Minthon L et al (2010) Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010. https://doi.org/10.4061/2010/986310

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University Hospital of Patras, University of Patras, Patras, Greece

    Panagiotis Alexopoulos

  2. Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany

    Panagiotis Alexopoulos

  3. Clinical and Molecular Oncology Laboratory, Division of Oncology, Medical Faculty, School of Health Sciences, University of Patras, Patras, Greece

    Chaido Sirinian

Authors
  1. Panagiotis Alexopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chaido Sirinian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Panagiotis Alexopoulos .

Editor information

Editors and Affiliations

  1. Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität München, Munich, Germany

    Robert Perneczky

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media, LLC

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Alexopoulos, P., Sirinian, C. (2018). Cerebrospinal Fluid Biomarkers of Preclinical Alzheimer’s Disease. In: Perneczky, R. (eds) Biomarkers for Preclinical Alzheimer’s Disease. Neuromethods, vol 137. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7674-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7674-4_6

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7673-7

  • Online ISBN: 978-1-4939-7674-4

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation